Dr Bakul Gupta is the CEO and Co-founder of ImmTune Therapies, a preclinical stage cell therapy biotech which is developing safe, scalable and affordable in vivo cell therapies.  The ambition is to enable an in vivo cell therapy process, whereby an injection of their product generates a dose of therapeutic cells, such as CAR-Ts, within the patient's body.  Bakul founded the company in 2019, along with her business partner, Dr George Tetley after a 6-month long research into the challenges faced by current cell and gene therapy companies. She completed her Postdoctoral fellowship at Imperial College London, and holds a PhD and BSc in Nanotechnology and Chemistry from UNSW Australia. She has over 10 years of experience in designing nano- and biomaterials for a diverse set of biomedical applications and has previous experience in commercialisation of medical devices. She was recently listed as one of the Top 30 biotech entrepreneurs to watch as part of a report produced by BioBeat.